Select Language 
English (Other Regions) 
VASCADE MVP®
Early Ambulation. Simple. Proven.
VASCADE MVP® vascular closure system provides rapid hemostasis for electrophysiology (EP) procedures, eliminating the need for manual compression and enabling patients to get up and moving earlier. In the AMBULATE Trial,1 the VASCADE MVP system has been proven to reduce time to ambulation by 64%, improve patient satisfaction by 63% and reduce opioid use post procedure by 58%. The VASCADE MVP system is the first and only FDA-approved closure device for same day discharge as well as for use in multi-stick, multi-limb cardiac ablation procedures.2 Watch the video
VASCADE MVP® System
Make a selection to learn more
VASCADE MVP® System
Early ambulation enables all stakeholders to accomplish their goals
Ordering Information
|
AMBULATE Trial
The impact of early ambulation using the VASCADE MVP® system is that every stakeholder has the potential to accomplish their specific goals and objectives. Each hospital will have distinct goals but all goals have an impact on the EP physicians, lab and nursing staff, hospital administration and patients. Potential goals can be same day discharge, patient satisfaction, opioid reduction, urinary catheter reduction, greater throughput, managing limited bed space and lowering overall costs. With the evolution of post-ablation workflow from manual compression and overnight stay to ambulation in 2 hours and same day discharge, the VASCADE MVP system is leading a new era in vascular closure.
Designed for EP procedures
Ordering Information
|
AMBULATE Trial
The VASCADE MVP® system is the only vascular closure device approved for multi-access, multi-limb closure2,3 and is the only extravascular closure device to offer collagen with a dual method of action, mechanical and physiological. Using a single operator, the VASCADE MVP system is simple and easy to use and leaves no sutures or other materials left behind in the vessel. The bioabsorbable thrombogenic plug expands by 13X to fill the tissue tract. VASCADE MVP venous vascular closure system can be used to re-access repeat ablation procedures.
.jpg)
Proven by EPs
Ordering Information
|
AMBULATE Trial
VASCADE MVP® venous vascular closure system has been proven in the prospective, multicenter randomized AMBULATE Clinical Trial,1 demonstrating a 3.9 hour (64%) reduction in median time to ambulation as well a 63% improvement in patient satisfaction and a 58% reduction in opioid use post ablation, when compared to manual compression. The VASCADE MVP system has also demonstrated same day discharge success in the retrospective and prospective multicenter AMBULATE Same Day Discharge Clinical Studies,5-6 where 90% of patients were sent home the same day using the VASCADE MVP system.6 In addition, 99% of VASCADE MVP same day discharge patients had no intervention during follow up5-7 and there were zero (0%) major complications.8
The first and only FDA-approved closure device for same day discharge
and multi-stick, multi-limb access following cardiac ablations2,3
• Dedicated to mid-bore 6-12F ID (Max 15F OD) multiaccess venous closure
• Simple and easy to use
• Single operator
• No sutures or material left in the vessel
• Extravascular design
• No permanent or intraluminal implants
• Bioabsorbable and thrombogenic collagen plug
• Expands to fill tissue tract
Related Training & Resources
Back to top
Webinars
Resource Center
Featured Resources View all resources
Instructions for Use
The VASCADE MVP® Venous Vascular Closure System (VVCS) is intended to seal the femoral vein access site(s) by delivering a resorbable collagen patch, extra-vascularly, at the venotomy site to aid in achieving hemostasis.
VASCADE MVP® Brochure
Our VASCADE MVP system provides rapid hemostasis for electrophysiology procedures, eliminating the need for manual compression and enabling patients to get up and moving earlier.
AMBULATE Trial
This prospective, multicenter, randomized study compared the efficacy and safety of VASCADE MVP® to manual compression for closing multiple access sites after catheter-based EP procedures.
AMBULATE Same Day Discharge Clinical Studies
This prospective, multicenter single arm registry evaluates procedural outcomes using VASCADE MVP® following atrial fibrillation interventions for patients who are discharged the same day.
Ordering Information
| Model Number | Description | Order Quantity |
| 800-612C-10U | 6-12 French (Inner Diameter) | 1 Box (10 devices per box) |
| Model Number | Description | Order Quantity |
| 700-500DX-05U | 5 French (Inner Diameter) | 1 Box (5 devices per box) |
| Model Number | Description | Order Quantity |
| 700-580I-05U | 6/7 French (Inner Diameter) | 1 Box (5 devices per box) |
| Product Name | Model Number | Description | Order Quantity |
| CATALYST II |
500-580C-10U | 5-7 French |
1 Box (10 devices per box) |
| CATALYST III |
600-580CP-10U |
5-7 French |
1 Box (10 devices per box) |
2. IFUs of commercially available venous vascular closure devices: VASCADE MVP®, MYNXGRIP®, Perclose ProGlide™ and Perclose ProStyle™. As of 1 Oct 2022.
3. Catheter-based cardiac ablations requiring two or more venous access sites within the same limb. See VASCADE MVP IFU 3972 Indications for Use.
4. AMBULATE IMPACT Study, April 2018. EX 4372, data on file at Haemonetics.
5. AMBULATE Same Day Discharge Registry Retrospective Study: NCT04538781.
6. AMBULATE Same Day Discharge Registry Prospective Studies (Paroxysmal AF): NCT04203329.
7. For venous access site closure-related complications through 15-day follow up or standard of care follow up, and for procedure- related complications the next day.
8. Major venous access site closure-related complications through the follow-up period.
Connect with Vascular Closure
